- The Scientific Director: Prof. Dr. Frans Ramaekers
- Leaders of the Division Developmental Biology: Prof. Christine E.M. de Die-Smulders and Prof. Dr. Luc Zimmerman
- Leaders of the Division Oncology: Prof. Dr. Philippe Lambin and Prof. Dr. Manon van Engeland
The Board is responsible for decision making on all activities within the Research School, herein assisted by the Managing Director. The Institute Board meets on the first Thursday of each month.
Managing Director a.i.: Judith Doomen.
The daily management is the responsibilty of the Scientific Director and the Managing Director, supported in their tasks by the Secretary.
Secretary's Office: Brigitte Custers
Besides these monthly Board meetings the Project Leaders participating within the Research school meets once a month.
The total number of scientific and support staff participation within GROW approximates 320, including 120 PhD students.
Prof. F.C.S. Ramaekers, PhD
Molecular Cell Biologist
Department of Molecular Cell Biology
Phone: +31 (0)43 38 813 51
Professor Frans C.S. Ramaekers (1952) was trained as a chemist at the University of Nijmegen, specialized in Biochemistry at the Universityof Nijmegen and Pharmaco-chemistry at Organon, Oss, and graduated in 1977. He received his PhD degree in 1981 at the Universityof Nijmegen on basis of a thesis on the role of the cytoskeleton in cell differentiation.
From 1981 to 1990 he was appointed as associate professor at the Department of Pathology of the University Hospital in Nijmegen, where studies on the application of cytoskeletal elements in cancer diagnosis were performed. In 1989 he received the Bristol-Meyers Oncology Award for this work.
In June 1989 he was appointed professor of Molecular Cell Biology at the Maastricht University and became chairman of the Department of Molecular Cell Biology & Genetics.
He has been president of the European Cytoskeleton Forum, chairman of the Dutch Society for Cell Biology, member of the board of the Dutch Society for Oncology, of the Federation of Medical Scientific Societies and of the Society of Experimental Biology (UK), and is member of the editorial board of several international journals, including Cytometry, Applied Immuno-histochemistry, Molecular Biology Reports, and Progress in Histochemistry and Cytochemistry.
He has published over 450 peer-reviewed papers and over 50 book contributions and national papers. He is scientific director of MUbio Products B.V.
As of March 2010 he has been appointed as scientific director of GROW - School for Oncology and Developmental Biology, Maastricht University Medical Center, for a period of six years.
Prof. M. van Engeland, PhD
Department of Pathology
Phone: +31 (0)43 388 5498
Professor Manon van Engeland studied Biological Health Sciences at Maastricht University, graduated in 1995 and obtained a PhD in Cell Biology 1999 at Maastricht University.
In 2000, she moved to the US to perform a postdoctoral fellowship in the laboratory of Prof. James G. Herman and Stephen B. Baylin at the Johns Hopkins University School of Medicine (Baltimore, USA).
During this fellowship she developed a strong interest in translational cancer epigenetics, particularly in the identification of promoter CpG island hypermethylated tumor suppressor genes.
Upon her return to Maastricht University in 2001, she started her research line on translational cancer epigenetics and founded the Cancer Pathology Laboratory at the dept. of Pathology at Maastricht University Medical Center, which she is currently heading.
She was appointed Assistant Professor and Associate Professor in 2003 and 2007 resp. Since 2009, she is division leader Oncology at GROW-the School for Oncology and Developmental Biology at Maastricht University Medical Center.
In March 2011 she was appointed as extraordinary professor pathobiology of cancer, specifically the role of epigenetics. She has obtained grants from the Dutch Cancer Society, ZONMW, SenterNovem and CTMM. For the CTMM DeCoDe project she is the deputy coordinator.
She has supervised 7 PhD projects, co-authored over 60 scientific papers in peer-reviewed journals and is co-inventor of three patents. Prof. van Engeland's laboratory is focussing on translational cancer epigenetics aiming to identify promoter methylation markers for early detection and prediction of prognosis and response to therapy in colorectal-, breast-, kidney and skin cancer.
Prof. P. Lambin, MD, PhD
Department of Radiation Oncology
Phone: +31 (0)88 44 55 754
Philippe Lambin is a Clinician, Radiation Oncologist and pioneer in translational research with a focus on hypoxia and Decision Support Systems. He has a PhD in Radiation Biology and is Professor at the University of Maastricht (Radiation Oncology) and at the University of Eindhoven (“Functional Imaging”).
He is co-author of more than 337 peer reviewed scientific papers (Hirsch Index: 51 (Scopus)-59 (Google Scholar)), co-inventor of more than 15 patents (filed or submitted) of which 5 are in the (pre)commercialization phase and (co) promoter of more than 30 completed PhD’s. Moreover, Prof. P. Lambin has extensive experience with clinical trials. He was one of the international experts in the Flims workshop “Methods in Clinical Cancer Research organised jointly by the FECS, AACR and ASCO and he is leading several clinical trials (see www.clinicaltrials.gov: his name is mentioned as Principal Investigator in 26 clinical trials).
He was also a member of the scientific committee of KWF (the main Dutch funding body in cancer research) and of the advice committee on protontherapy of CVZ (the Dutch medical insurance). He is currently involved in several successful European grants (e.g. CDPT, Biocare, Euroxy, Metoxia, euroCAT, Eureca, Artforce, Radiate, Requite…) and one NIH grant (“Radiomics”).
His main areas of interest are directed towards translational research in Radiation Biology with a specific focus on tumour hypoxia, functional imaging (CT-PET), lung and head and neck cancer. More recently his interests have been directed towards the development of a “treatment decision support system” based on multiparametric databases containing clinical, imaging, biological and therapeutic information, and taking into account patient preferences (visit one of the websites he is managing: www.predictcancer.org).
In September 2012, his research group received the highest possible score (‘excellent’ – 5 - on all aspects) by an external review committee and was described as having a “world-leading position”. The reviewers added “In large part, this is due to the inspirational leadership Prof. P. Lambin who has done an outstanding job of building a world-class research programme within a relatively short period of time.” In February 2014, MAASTRO clinic received a licence from the Dutch Ministry of Health to start protontherapy in Maastricht. Since he started as medical Director of MAASTRO in 2000 the volume of activities, the number of FTE and the annual budget more then tripled.
Prof. L.J.I. Zimmermann, MD, PhD
Department of Pediatrics
Phone: +31 (0)43 38 77 250
Professor Luc J.I. Zimmermann was born in 1959 in Belgium. He graduated as MD in 1984 at the Catholic University of Leuven, Belgium and did his residency in Pediatrics at the same university, in the University Hospital Gasthuisberg Leuven, Belgium (1984-1989).
He trained as a Fellow in Neonatology at the Hospital for Sick Children and the University of Toronto Perinatal Fellowship Program in Toronto, Canada from 1989 to 1992. From 1992 to 2003 he was a staff Neonatologist at the Erasmus Medical Center – Sophia in Rotterdam, where he was Chief of the Division of Neonatology a.i. from 2000 to 2003.
His PhD thesis (in 1995) was titled "Regulation of CTP:phosphocholine cytidylyltransferase in fetal type II cells". In 2003 he became a staff neonatologist at the Academic Hospital Maastricht, in 2004 Professor in Pediatrics and in 2005 Chief of the Division of Neonatology.
In 2006 he became Chairman of the Department of Pediatrics and Director of the Residency Program in Pediatrics. In July 2006 he took over as Division leader in GROW from Carlos